Survival outcomes based on line of therapy and treatment trends with cabazitaxel in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). Term Induction phase Arm A (q4w) Arm B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results